The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 347:781-789 September 12, 2002 Number 11
NextNext

A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer
Lars Holmberg, M.D., Ph.D., Anna Bill-Axelson, M.D., Fred Helgesen, M.D., Jaakko O. Salo, M.D., Ph.D., Per Folmerz, M.D., Michael Häggman, M.D., Ph.D., Swen-Olof Andersson, M.D., Ph.D., Anders Spångberg, M.D., Christer Busch, M.D., Ph.D., Steg Nordling, M.D., Ph.D., Juni Palmgren, Ph.D., Hans-Olov Adami, M.D., Ph.D., Jan-Erik Johansson, M.D., Ph.D., Bo Johan Norlén, M.D., Ph.D., for the Scandinavian Prostatic Cancer Group Study Number 4

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Walsh, P. C.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Radical prostatectomy is widely used in the treatment of early prostate cancer. The possible survival benefit of this treatment, however, is unclear. We conducted a randomized trial to address this question.

Methods From October 1989 through February 1999, 695 men with newly diagnosed prostate cancer in International Union against Cancer clinical stage T1b, T1c, or T2 were randomly assigned to watchful waiting or radical prostatectomy. We achieved complete follow-up through the year 2000 with blinded evaluation of causes of death. The primary end point was death due to prostate cancer, and the secondary end points were overall mortality, metastasis-free survival, and local progression.

Results During a median of 6.2 years of follow-up, 62 men in the watchful-waiting group and 53 in the radical-prostatectomy group died (P=0.31). Death due to prostate cancer occurred in 31 of 348 of those assigned to watchful waiting (8.9 percent) and in 16 of 347 of those assigned to radical prostatectomy (4.6 percent) (relative hazard, 0.50; 95 percent confidence interval, 0.27 to 0.91; P=0.02). Death due to other causes occurred in 31 of 348 men in the watchful-waiting group (8.9 percent) and in 37 of 347 men in the radical-prostatectomy group (10.6 percent). The men assigned to surgery had a lower relative risk of distant metastases than the men assigned to watchful waiting (relative hazard, 0.63; 95 percent confidence interval, 0.41 to 0.96).

Conclusions In this randomized trial, radical prostatectomy significantly reduced disease-specific mortality, but there was no significant difference between surgery and watchful waiting in terms of overall survival.


Source Information

From the Regional Oncologic Center (L.H.) and the Department of Urology (A.B.-A., M.H., B.J.N.), University Hospital, Uppsala, Sweden; the Center for Assessment of Medical Technology (F.H., J.-E.J.) and the Department of Urology (S.-O.A., J.-E.J.), Örebro University Hospital, Örebro, Sweden; the Department of Urology, Helsinki University Hospital, Helsinki, Finland (J.O.S.); the Department of Urology, Borås Hospital, Borås, Sweden (P.F.); the Department of Urology, University Hospital, Linköping, Sweden (A.S.); the Department of Pathology, University Hospital, Tromsö, Norway (C.B.); the Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland (S.N.); the Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden (J.P., H.-O.A.); and the Department of Epidemiology and the Harvard Center for Cancer Prevention, Harvard School of Public Health, Boston (H.-O.A.).

Drs. Johansson and Norlén contributed equally to the article.

Address reprint requests to Dr. Bill-Axelson at the Department of Urology, University Hospital, SE-751 85 Uppsala, Sweden, or at anna.bill-axelson{at}urologi.uas.lul.se.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.